These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 31119266)

  • 21. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?
    Chao TF; Liu CJ; Wang KL; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chen TJ; Lip GY; Chen SA
    J Am Coll Cardiol; 2015 Feb; 65(7):635-42. PubMed ID: 25677422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The personalized antithrombotic management of atrial fibrillation with intermediate thromboembolic risk: a case report.
    Hammer A; Schnaubelt S; Niessner A; Sulzgruber P
    Eur Heart J Case Rep; 2020 Oct; 4(5):1-4. PubMed ID: 33204971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticoagulant Therapy in Atrial Fibrillation for Stroke Prevention: Assessment of Agreement Between Clinicians' Decision and CHA2DS2-VASc and HAS-BLED Scores.
    Balaghi-Inalou M; Parsa SA; Gachkar L; Andalib S
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):61-64. PubMed ID: 29076078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The CHA
    Jia X; Levine GN; Birnbaum Y
    Int J Cardiol; 2018 Apr; 257():92-96. PubMed ID: 29506745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Characterisation of thromboembolic risk in a mexican population with non-valvular atrial fibrillation and its effect on anticoagulation (MAYA Study)].
    Vázquez-Acosta JA; Ramírez-Gutiérrez ÁE; Cerecedo-Rosendo MA; Olivera-Barrera FM; Tenorio-Sánchez SS; Nieto-Villarreal J; González-Borjas JM; Villanueva-Rodríguez E
    Gac Med Mex; 2016; 152(4):473-8. PubMed ID: 27595250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.
    Olesen JB; Torp-Pedersen C; Hansen ML; Lip GY
    Thromb Haemost; 2012 Jun; 107(6):1172-9. PubMed ID: 22473219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
    Lip GYH; Collet JP; de Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B
    Thromb Haemost; 2017 Dec; 117(12):2215-2236. PubMed ID: 29212110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stroke Risk Stratification Schemes in Atrial Fibrillation in the Era of Non- Vitamin K Anticoagulants: Misleading and Obsolete, At Least for the "Low-Risk" Patients?
    Manolis AS; Manolis TA; Manolis AA; Melita H
    Curr Drug Targets; 2017 Nov; 18(16):1852-1865. PubMed ID: 27593686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Practice Gap in Atrial Fibrillation Oral Anticoagulation Prescribing at Emergency Department Home Discharge.
    Kea B; Waites BT; Lin A; Raitt M; Vinson DR; Ari N; Welle L; Sill A; Button D; Sun BC
    West J Emerg Med; 2020 Jun; 21(4):924-934. PubMed ID: 32726266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SUPPORT-AF II: Supporting Use of Anticoagulants Through Provider Profiling of Oral Anticoagulant Therapy for Atrial Fibrillation: A Cluster-Randomized Study of Electronic Profiling and Messaging Combined With Academic Detailing for Providers Making Decisions About Anticoagulation in Patients With Atrial Fibrillation.
    Kapoor A; Amroze A; Vakil F; Crawford S; Der J; Mathew J; Alper E; Yogaratnam D; Javed S; Elhag R; Lin A; Narayanan S; Bartlett D; Nagy A; Shagoury BK; Fischer MA; Mazor KM; Saczynski JS; Ashburner JM; Lopes R; McManus DD
    Circ Cardiovasc Qual Outcomes; 2020 Feb; 13(2):e005871. PubMed ID: 32063041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reasons for and consequences of oral anticoagulant underuse in atrial fibrillation with heart failure.
    Savarese G; Sartipy U; Friberg L; Dahlström U; Lund LH
    Heart; 2018 Jul; 104(13):1093-1100. PubMed ID: 29371374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.
    Lip GYH; Banerjee A; Boriani G; Chiang CE; Fargo R; Freedman B; Lane DA; Ruff CT; Turakhia M; Werring D; Patel S; Moores L
    Chest; 2018 Nov; 154(5):1121-1201. PubMed ID: 30144419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc ≥1, or higher?
    Olesen JB; Torp-Pedersen C
    Thromb Haemost; 2015 Jun; 113(6):1165-9. PubMed ID: 25743201
    [No Abstract]   [Full Text] [Related]  

  • 35. Usefulness of the CHA
    Jaakkola S; Kiviniemi TO; Nuotio I; Hartikainen J; Mustonen P; Palomäki A; Jaakkola J; Ylitalo A; Hartikainen P; Airaksinen KEJ
    Am J Cardiol; 2018 May; 121(10):1182-1186. PubMed ID: 29526276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study.
    Taillandier S; Olesen JB; Clémenty N; Lagrenade I; Babuty D; Lip GY; Fauchier L
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):708-13. PubMed ID: 22268375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).
    De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Kerschnitzki M; Reimitz PE; Kirchhof P;
    BMC Cardiovasc Disord; 2019 Jul; 19(1):165. PubMed ID: 31299906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Anticoagulation and new therapeutic options in atrial fibrillation].
    Mischke K
    Dtsch Med Wochenschr; 2016 Oct; 141(22):1618-1623. PubMed ID: 27824417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation.
    Jacobs V; May HT; Bair TL; Crandall BG; Cutler M; Day JD; Weiss JP; Osborn JS; Muhlestein JB; Anderson JL; Mallender C; Bunch TJ
    Heart Rhythm; 2015 Apr; 12(4):681-6. PubMed ID: 25546809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.
    Fox KAA; Lucas JE; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Hacke W; Kayani G; Oto A; Mantovani LG; Misselwitz F; Piccini JP; Turpie AGG; Verheugt FWA; Kakkar AK;
    BMJ Open; 2017 Dec; 7(12):e017157. PubMed ID: 29273652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.